New hope for hard-to-treat pancreatic cancer: targeted drug combo enters phase 3 trial
NCT ID NCT07621718
First seen Jun 27, 2026 · Last updated Aug 04, 2026 · Updated 4 times
Summary
This study tests whether adding an experimental drug called zoldonrasib to standard chemotherapy helps people with a specific genetic form of metastatic pancreatic cancer (KRAS G12D mutation) live longer without their cancer growing. About 670 adults with advanced pancreatic cancer that has spread will receive either the drug combo or a placebo plus chemo. The goal is to see if the targeted therapy improves survival and slows disease progression.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC KRAS G12D-MUTATED PANCREATIC ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
Johns Hopkins University
RECRUITINGBaltimore, Maryland, 21287, United States
Contact Email: •••••@•••••
-
Moffitt Cancer Center
RECRUITINGTampa, Florida, 33612, United States
-
Piedmont Healthcare
RECRUITINGAtlanta, Georgia, 30318, United States
-
The University of Arizona Cancer Center-North Campus
RECRUITINGTucson, Arizona, 85719, United States
-
University of Chicago Medical Center
RECRUITINGChicago, Illinois, 60637, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Two-Drug immune attack shrink Hard-to-Treat pancreatic tumors?
- Could a vaccine help fight Hard-to-Treat cancers?
- Blood and gut clues may flag pancreatic cancer risk early
- A high-tech camera may take the guesswork out of spotting a dangerous surgery complication
- MRI might reveal hidden pancreatic risks in obesity
- Can a new PET tracer light up hidden cancers?